RPG Investment Advisory LLC Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

RPG Investment Advisory LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the fourth quarter, Holdings Channel reports. The fund owned 83,633 shares of the biopharmaceutical company’s stock after selling 245 shares during the period. RPG Investment Advisory LLC’s holdings in Gilead Sciences were worth $7,725,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Finally, Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on GILD shares. Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Bank of America reaffirmed a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Royal Bank of Canada upped their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Stock Down 0.1 %

Shares of NASDAQ:GILD opened at $109.95 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $111.03. The company has a 50-day moving average price of $95.41 and a 200 day moving average price of $88.83. The company has a market cap of $137.03 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.